Cyclacel Pharmaceuticals Inc  

(Public, NASDAQ:CYCC)   Watch this stock  
Find more results for CYCC
4.00
-0.12 (-2.91%)
Dec 9 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.00 - 4.30
52 week 3.05 - 9.72
Open 4.10
Vol / Avg. 66,225.00/127,399.00
Mkt cap 16.75M
P/E     -
Div/yield     -
EPS -4.08
Shares 4.25M
Beta 3.20
Inst. own 19%
Nov 14, 2016
Q3 2016 Cyclacel Pharmaceuticals Inc Earnings Call
Nov 14, 2016
Q3 2016 Cyclacel Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -1437.07% -737.76%
Operating margin -1696.10% -831.79%
EBITD margin - -820.99%
Return on average assets -56.91% -52.97%
Return on average equity -79.84% -71.78%
Employees 16 -
CDP Score - -

Address

200 Connell Dr Ste 1500
BERKELEY HEIGHTS, NJ 07922-2811
United States - Map
+1-908-5177330 (Phone)
+1-866-2713466 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.

Officers and directors

David C. U'Prichard Ph.D. Independent Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Spiro George Rombotis President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Christopher S. Henney Ph.D. Independent Vice Chairman of the Board
Age: 75
Bio & Compensation  - Reuters
Paul McBarron Chief Financial Officer, Chief Operating Officer, Executive Vice President - Finance, Secretary, Director
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Judy H. Chiao M.D. Vice President - Clinical Development and Regulatory Affairs
Age: 55
Bio & Compensation  - Reuters
Samuel L. Barker Ph.D. Director
Age: 72
Bio & Compensation  - Reuters
John Michael Middlecott Banham Independent Director
Age: 74
Bio & Compensation  - Reuters
Gregory T. Hradsky Independent Director
Age: 54
Bio & Compensation  - Reuters
Lloyd M Sems Independent Director
Age: 44
Bio & Compensation  - Reuters